CareDx (CDNA) Stock Forecast & Price Target

CareDx Inc. reported a 21% increase in top-line revenue during Q3, driven by a combination of 13% volume growth and a 5% increase in average selling prices, achieving record cash collections in October. The company has significantly expanded its sales force by approximately 50%, which is expected to enhance volume growth moving forward, especially following a solid 19% year-over-year growth in kidney surveillance volumes reported earlier. Additionally, CareDx achieved positive GAAP net income and raised its financial guidance, further underscoring the company's strengthening financial performance and positive outlook.

CareDx Inc. has reported that Q3 2025 testing volumes increased by 13% year-over-year, but the total volume of 50,000 fell short of expectations, indicating potential seasonality issues and a slowdown in growth momentum. The company's shares remain under pressure, trading at 1.4 times the 2026 revenue estimate of $415 million, a substantial discount compared to historical averages of 3-7 times and lower than peers in the diagnostics sector, which trade at 9-10 times. Additionally, the company's growth strategy may be compromised by challenges in commercializing new diagnostic solutions, management turnover over the past three years, and uncertainty surrounding potential adjustments in Medicare testing limits that could limit future revenue growth.